Results 101 to 110 of about 25,818 (186)
Thoracic Cancer, 2019 Background Approximately 3%–5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors.
Shih‐Hao Huang +11 more
doaj +1 more source
Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 2013 At present, in the treatment of non-small cell lung cancer (NSCLC), targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), crizotinib targeted at EML4-ALK fusion gene becomes a significant ...
Haibo ZHU, Xiaoyu XU, Ling WANG
doaj +1 more source
Seguimiento terapéutico del Paciente con cáncer de pulmón no microcítico en tratamiento con inhibidores de la tirosina cinasa (itc) [PDF]
, 2016 Aproximadamente, el 85% de los canceres de pulmón diagnosticados, son de tipo no microcítico, siendo el subtipo adenocarcinoma el más frecuente. Los inhibidores de la tirosina cinasa (ITC) son fármacos orales cuyo uso ha supuesto una nueva alternativa ...
Arauzo Gimeno, Beatriz
core
Stromal cell effects on melanoma cell drug response [PDF]
, 2013 Thesis (M.A.)--Boston UniversityObjective: Melanoma is currently one of the deadliest forms of skin disease in the United States. However in the past decade there have been significant advances in treatment.
Della Penna, Greg
core +1 more source
Pharmacogenomics and Personalized Medicine, 2015 Hazem El-Osta,1 Rodney Shackelford2 1Department of Medicine, 2Department of Pathology, Feist-Weiller Cancer Center, Louisiana State University Health Science Center-Shreveport, Shreveport, LA, USA Abstract: The fusion of echinoderm microtubule ...
El-Osta H, Shackelford R
doaj
Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
International Medical Case Reports Journal, 2020 Pietro Di Marino,1 Gianluca Mannetta,2 Consiglia Carella,3 Antonino Grassadonia,3 Nicola Tinari,3 Clara Natoli,3 Michele De Tursi3 1Clinical Oncology Unit, S.S.
Di Marino P +6 more
doaj
Detection of tumor ALK status in neuroblastoma patients using peripheral blood
, 2015 International audienceNew protocols based on ALK-targeted therapy by crizotinib or other ALK-targeting molecules have opened for the treatment of patients with neuroblastoma (NB) if their tumors showed mutation and/or amplification of the ALK gene ...
Barone +28 more
core +3 more sources
Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system [PDF]
, 2018 Achilefu, Samuel +5 more
core +2 more sources
, 2017 a substantial proportion of non-small-cell lung cancer (NSCLC), and adenocarcinoma in particular, depends on a so-called ‘driver mutation' for their malignant phenotype.
Peters, S., Zimmermann, S.
core
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. [PDF]
, 2019 BackgroundA previous analysis of 113 National Comprehensive Cancer Network® (NCCN®) recommendations reported that NCCN frequently recommends beyond Food and Drug Administration (FDA)-approved indications (44 off-label recommendations) and claimed that ...
Benson, AB +8 more
core